B

ERLIN--GPC, a genomics-based drug discovery company headquartered in Munich, and Atugen, a target discovery and validation company here, announced a strategic alliance to provide life sciences companies with an integrated functional genomics and proteomics platform to identify and validate novel drug discovery targets. The combined technology platforms can be applied to major diseases such as cancer and metabolic disorders as well as central nervous system and heart ailments.